Abby Hardy, Author at BioTuesdays

Developments

Zenabis outperforms revised cannabis design capacity by 41% in August

Zenabis Global’s (TSX:ZENA) cultivation output in August 2019 was 1,996 kg of dried cannabis, 40.9% greater than its revised design capacity and 26.4% greater than its Aug. 6 revised forecast output of 1,579 kg of dried...

September 18, 2019

Developments

Anika Therapeutics launches TACTOSET bone repair therapy in the U.S.

Anika Therapeutics (NASDAQ: ANIK) launched its injectable hyaluronic acid (HA) enhanced bone repair therapy, TACTOSET, in the U.S. for the treatment of bone voids and other bone defects. TACTOSET is an injectable, HA...

September 18, 2019

Developments

FDA approves Kadmon Holdings’ generic Wilson’s disease drug

The FDA approved Kadmon Holdings’ (NYSE:KDMN) generic trientine hydrochloride capsules for the treatment of Wilson’s disease patients who are intolerant of penicillamine. Wilson’s disease is a genetic disorder caused by...

September 18, 2019

Executive Moves

MDBriefCase names Drs. David Strain and Mohamed Farghaly as new expert advisors

Online continuing professional development provider, MDBriefCase Group (MDBC), is collaborating with Dr. David Strain, senior clinical lecturer at the University of Exeter and Dr. Mohamed Farghaly, associate professor...

September 18, 2019

Developments

Titan Pharma gets second year of NIDA funding for nalmefene implant development

The National Institutes of Health’s National Institute on Drug Abuse (NIDA) approved $6.1-million in second-year funding for Titan Pharmaceuticals‘ (NASDAQ:TTNP) development of a nalmefene implant. Titan is using...

September 18, 2019

Markets

WB starts Axsome Therapeutics at OP; fair value estimate $48

William Blair initiated coverage of Axsome Therapeutics (NASDAQ:AXSM) with an “outperform” rating and a fair value estimate of $48. The stock closed at $28.21 on Sept. 17. Axsome Therapeutics is focused on developing...

September 18, 2019

Developments

iBio expands collaboration with AzarGen to develop plant-made rituximab

iBio (NYSE AMERICAN:IBIO) advanced its collaboration with closely-held AzarGen Biotechnologies by initiating development of a plant-made rituximab for the South African market. iBio previously used its FastPharming...

September 17, 2019

Developments

Concert Pharma completes enrollment in second open label alopecia areata trial

Concert Pharmaceuticals (NASDAQ:CNCE) completed enrollment in its second open label trial comparing once-daily versus twice-daily dosing of CTP-543, a deuterium-modified ruxolitinib, in alopecia areata patients...

September 17, 2019

Markets

SVB Leerink starts Axonics Modulation at OP; PT $45

SVB Leerink initiated coverage of Axonics Modulation Technologies (NASDAQ:AXNX) with an “outperform” rating and $45 price target. The stock closed at $30.27 on Sept. 16. “To us, Axonics represents a hyper-growth story...

September 17, 2019

Developments

Allena Pharma completes enrollment in first of two Phase 3 enteric hyperoxaluria trials

Allena Pharmaceuticals (NASDAQ:ALNA) has completed enrollment in the first of two Phase 3 clinical trials of reloxaliase for the treatment of enteric hyperoxaluria. Enteric hyperoxaluria occurs when an underlying...

September 16, 2019

Author - Abby Hardy

Zenabis outperforms revised cannabis design capacity by 41% in August

Anika Therapeutics launches TACTOSET bone repair therapy in the U.S.

FDA approves Kadmon Holdings’ generic Wilson’s disease drug

MDBriefCase names Drs. David Strain and Mohamed Farghaly as new expert advisors

Titan Pharma gets second year of NIDA funding for nalmefene implant development

WB starts Axsome Therapeutics at OP; fair value estimate $48

iBio expands collaboration with AzarGen to develop plant-made rituximab

Concert Pharma completes enrollment in second open label alopecia areata trial

SVB Leerink starts Axonics Modulation at OP; PT $45

Allena Pharma completes enrollment in first of two Phase 3 enteric hyperoxaluria trials

Follow Us

Subscribe

General

More

Subscribe